In Vivo Bioluminescent Monitoring of Parasites in BALB/c Mouse Models of Cutaneous Leishmaniasis Drug Discovery

Caridha, Diana; Leed, Susan E.; Cawlfield, Alicia

doi:10.1007/978-1-4939-9940-8_7

Cited by 3 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, it is important to determine in the strategy of the choice of the animal model, the appropriate method to follow the infectious state of the animal. The conventional methods such as microscopy or q-PCR amplification of parasite DNA, are laborious, time consuming and require the euthanasia of large numbers of animals [202,210]. These methods cannot detect the spread of pathogens to unexpected anatomic sites or monitor their space/time progression.…”

Section: Future Perspectives: Drug Delivery In Combination With Wound...mentioning

confidence: 99%

“…imaging system without needing to euthanize the animal [210]. This is an ideal refinement for conducting longitudinal studies in a more non-invasive in vivo drug screening model and parasite-host interaction studies [212].…”

Section: Importance Of the Inoculum In Model Developmentmentioning

confidence: 99%

“…The use of the firefly luciferase reporter molecule in transgenic Leishmania species showed promising results in drug evaluation due to its high sensitivity [211]. It is then possible to follow the infectious evolution in the animal using a bioluminescence imaging system without needing to euthanize the animal [210]. This is an ideal refinement for conducting longitudinal studies in a more non-invasive in vivo drug screening model and parasite–host interaction studies [212].…”

Section: Future Perspectives: Drug Delivery In Combination With Wound...mentioning

confidence: 99%

See 2 more Smart Citations

Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis

et al. 2022

View full text Add to dashboard Cite

Nanomedicine strategies were first adapted and successfully translated to clinical application for diseases, such as cancer and diabetes. These strategies would no doubt benefit unmet diseases needs as in the case of leishmaniasis. The latter causes skin sores in the cutaneous form and affects internal organs in the visceral form. Treatment of cutaneous leishmaniasis (CL) aims at accelerating wound healing, reducing scarring and cosmetic morbidity, preventing parasite transmission and relapse. Unfortunately, available treatments show only suboptimal effectiveness and none of them were designed specifically for this disease condition. Tissue regeneration using nano-based devices coupled with drug delivery are currently being used in clinic to address diabetic wounds. Thus, in this review, we analyse the current treatment options and attempt to critically analyse the use of nanomedicine-based strategies to address CL wounds in view of achieving scarless wound healing, targeting secondary bacterial infection and lowering drug toxicity.

show abstract

Section: Future Perspectives: Drug Delivery In Combination With Wound...mentioning

confidence: 99%

Section: Importance Of the Inoculum In Model Developmentmentioning

confidence: 99%

Section: Future Perspectives: Drug Delivery In Combination With Wound...mentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In vivo imaging systems (IVIS) offer a way to monitor the progress of an infection in a noninvasive manner. IVIS has been used to study and evaluate drug and vaccine efficacy in intracellular eukaryotic parasitic [12][13][14], bacterial [15] and viral infections [16]. IVIS relies on the use of transgenic parasites expressing a florescent reporter protein, whose presence can be detected with a highly sensitive charged coupled device (CCD) camera.…”

Section: Introductionmentioning

confidence: 99%

In vivo imaging of transgenic Brugia malayi

Liu

Miley

et al. 2020

PLoS Negl Trop Dis

View full text Add to dashboard Cite

BackgroundStudies of the human filarial parasite have been hampered by the fact that they are obligate parasites with long life cycles. In other pathogenic infections, in vivo imaging systems (IVIS) have proven extremely useful in studying pathogenesis, tissue tropism and in vivo drug efficacy. IVIS requires the use of transgenic parasites expressing a florescent reporter. Developing a method to produce transgenic filarial parasites expressing a florescent reporter would permit IVIS to be applied to the study of tissue tropism and provide a non-invasive way to screen for in vivo drug efficacy against these parasites. Methodology/Principal findingsWe report the development of a dual luciferase reporter construct in a piggyBac backbone that may be used to stably transfect Brugia malayi, a causative agent of human filariasis. Parasites transfected with this construct were visible in IVIS images obtained from infected gerbils. The signal in these infected animals increased dramatically when the transgenic parasites matured to the adult stage and began to produce transgenic progeny microfilaria. We demonstrate that the IVIS system can be used to develop an effective method for cryopreservation of transgenic parasites, to non-invasively monitor the effect of treatment with anti-filarial drugs, and to rapidly identify transgenic F1 microfilariae. ConclusionsTo our knowledge, this represents the first application of IVIS to the study of a human filarial parasite. This method should prove useful in studies of tissue tropism and as an efficient in vivo assay for candidate anti-filarial drugs.

show abstract